Aspire Biopharma Holdings, Inc.
ASBPNasdaqHealthcare · Pharmaceutical Preparations · E9 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | |
|---|---|---|---|---|---|
| Revenue | $6,202 | — | — | — | — |
| Operating income | −$19.4M | −$1.2M | — | — | — |
| Net income | −$24.5M | −$12.5M | $4.5M | $3.3M | −$25,475 |
| Total assets | $1.3M | $6.7M | $20.0M | $300.2M | $293,221 |
| Total liabilities | $7.7M | $15.6M | $403,328 | $11.1M | $293,696 |
| Equity | −$6.4M | −$15.6M | −$322,105 | −$9.9M | −$475 |
| EPS (diluted) | $-16.38 | $-1.90 | — | — | — |
| Shares out. | 48.9M | 690,044 | — | — | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −312016.9%
- Net margin
- −394725.1%
- Return on equity
- 383.9%
- Return on assets
- −1865.7%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 585.9%
- Debt / equity
- —
- Book value / share
- $-0.13
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -199.10distress
- Accruals / assets
- −1490.5%clean
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 4 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 31, 2025
- NT 10-Qmissed a reporting deadline ↗Aug 15, 2024
- NT 10-Qmissed a reporting deadline ↗May 15, 2024
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Highbridge Capital Management LlcPassive (13G)May 15, 2026
- Ardsley Advisory Partners LpPassive (13G)May 13, 2026
- Friedman LancePassive (13G)May 19, 2025
- Harraden Circle Investments, LlcPassive (13G)May 15, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 75,959 | 1.0 | -90.8% |
| Apr 30, 2026 | 821,485 | 1.0 | +120.0% |
| Apr 15, 2026 | 373,385 | 1.0 | -13.3% |
| Mar 31, 2026 | 430,841 | 1.0 | -13.9% |
| Mar 13, 2026 | 500,465 | 2.8 | +24.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Amended charter or bylawsMay 14, 2026
- Regulation FD disclosureApr 20, 2026
- Entered a material agreement · Amended charter or bylawsApr 16, 2026
- Shareholder voteApr 16, 2026
- Regulation FD disclosureApr 16, 2026
- Entered a material agreementApr 15, 2026
- Entered a material agreement · Unregistered equity sale · Director / officer change · Regulation FD disclosureFeb 12, 2026
- Amended charter or bylawsFeb 6, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.